Close Menu

NEW YORK – Fluidigm reported after the close of the market on Wednesday that its fourth quarter revenues increased 38 percent year over year as COVID-19 testing demand drove sales of the company's microfluidics products while the firm's mass cytometry business continued to recover from the early months of the pandemic.

Separately on Wednesday, Fluidigm said that George Mason University has begun providing campus-wide saliva-based COVID-19 testing with the firm's Advanta Dx SARS-CoV-2 RT-PCR assay on the Biomark HD microfluidics system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.